Rexahn Pharma (RNN) Initiates Archexin Proof-of-Concept Study in RCC StreetInsider.com (subscription) The Phase IIa Archexin proof-of-concept clinical trial is a multi-center study designed to evaluate the efficacy of Archexin in combination with everolimus (AfinitorĀ®) to treat metastatic RCC patients and will be conducted in two stages. Stage 1 will ... |
